Thalidomide reveals path for targeting undruggable transcription factors for cancer treatment

November 5, 2018 by Tom Ulrich, Broad Institute of MIT and Harvard
Thalidomide reveals path for targeting undruggable transcription factors for cancer treatment
Credit: Susanna M. Hamilton, Broad Communications

Thalidomide, a morning-sickness drug recalled in the 1960s because it caused devastating birth defects, is now commonly used to treat multiple myeloma and other blood cancers. It and its chemical relatives work by causing cells to destroy two proteins—members of a larger family of conventionally "undruggable" proteins called transcription factors—that feature a particular molecular pattern called a C2H2 zinc finger (ZF) motif.

Writing in the journal Science, researchers at the Broad Institute of MIT and Harvard, the Dana-Farber Cancer Institute, Brigham and Women's Hospital, and the University of Basel suggest that thalidomide and related drugs could provide a starting point for establishing a new class of cancer-fighting compounds, one that targets many more of the estimated 800 that harbor the same motif.

Transcription factors bind to DNA and coordinate the expression of large numbers of genes, often in patterns specific to certain cell types or tissues. Errors in these proteins are linked to many cancers, but scientists have found them exceedingly difficult to target them for drug development. This is because transcription factors lack sites where drug molecules can bind directly.

Thalidomide and its chemical relatives, pomalidomide and lenalidomide, rather, attack their targets (two C2H2 ZF-bearing transcription factors called IKZF1 and IKZF3) indirectly, by conscripting a protein called cereblon. Cereblon is part of a molecular machine called an E3 ubiquitin ligase, which flags proteins for destruction by the cell's recycling system.

When thalidomide and its cousins are absent, cereblon ignores IKZF1 and IKZF3. When present, however, they allow cereblon to recognize these transcription factors and mark them for disposal.

"The discovery of thalidomide's mechanism of action was surprising in many ways, but it showed us how to trigger the rapid degradation of two zinc finger transcription factors that we otherwise had no idea of how to drug," said Benjamin Ebert, an institute member in the Broad Cancer Program and the chair of medical oncology at DFCI.

The search for new roles for an old drug

The human genome encodes an estimated 800 transcription factors that, like IKZF1 and IKZF3, bear some variation of the C2H2 ZF motif. Recognizing an opportunity to open additional such factors up for drug development, the team—led by Ebert and Quinlan Sievers of the Broad, DFCI, and BWH; and Georg Petzold and Nicolas Thoma at the University of Basel—set out to discover whether other similar transcription factors might also be vulnerable to thalidomide-like drugs.

The team started by determining the precise C2H2 ZF features that cereblon "sees" when thalidomide-like drugs are present. They then screened thalidomide, pomalidomide, and lenalidomide for their ability to trigger degradation of 6,572 unique C2H2 ZF motif variations in cellular models. The screen revealed six C2H2 ZF-containing proteins that were vulnerable to the drugs, four of which scientists had not previously identified as targets for thalidomide or its relatives.

After conducting additional functional and structural studies of IKZF1 and IKZF3 to better understand how the transcription factors, cereblon, and thalidomide drugs interact, the team then ran computer models of 4,661 variations to see if they could predict additional transcription factors that might dock with cereblon in the presence of drug.

The computational data, together with follow-on biochemical studies, suggest that suitably modified thalidomide-like drugs should be able to "trick" cereblon into flagging specific subsets of C2H2 ZF transcription factors for recycling.

"It's extraordinary how specific these interactions are," Ebert said. "The drugs prompt the cell to degrade specific zinc finger transcription factors, leaving the other zinc finger proteins alone. It's a highly selective mechanism."

New answers, new questions

The findings raise many more questions then they answer. For instance, scientists know little about many of the C2H2 ZF transcription factors highlighted in this study: which cell types they are active in, which genes they affect, which cancers may depend on them. This knowledge would help researchers prioritize the factors they might want to target, and set the stage for creating new thalidomide derivatives to target them.

"But the take-home message," Ebert said, "is that there is a much broader array of zinc finger factors that may be amenable to drug-induced degradation than we had initially thought."

Explore further: After 60 years, scientists uncover how thalidomide produced birth defects

More information: Quinlan L. Sievers et al. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN, Science (2018). DOI: 10.1126/science.aat0572

Related Stories

After 60 years, scientists uncover how thalidomide produced birth defects

August 1, 2018
More than 60 years after the drug thalidomide caused birth defects in thousands of children whose mothers took the drug while pregnant, scientists at Dana-Farber Cancer Institute have solved a mystery that has lingered ever ...

Mechanism of action of thalidomide elucidated

July 17, 2014
(Medical Xpress)—Scientists led by Nicolas Thomä at the Friedrich Miescher Institute for Biomedical Research have clarified the workings of thalidomide at the molecular level. Their analysis of various structures, published ...

How patients will respond to immunomodulator therapy for multiple myeloma

December 11, 2011
Research on the same protein that was a primary mediator of the birth defects caused by thalidomide now holds hope in the battle against multiple myeloma, says the study's senior investigator, Keith Stewart, M.B., Ch.B. of ...

Scientists discover mechanism of thalidomide

June 17, 2016
In the 1950s, thalidomide (Contergan) was prescribed as a sedative drug to pregnant women, resulting in a great number of infants with serious malformations. Up to now, the reasons for these disastrous birth defects have ...

Recommended for you

Sugar supplement slows tumor growth and can improve cancer treatment

November 21, 2018
Mannose sugar, a nutritional supplement, can both slow tumour growth and enhance the effects of chemotherapy in mice with multiple types of cancer.

New mechanism controlling the master cancer regulator uncovered

November 21, 2018
Who regulates the key regulator? The Research Center for Molecular Medicine of the Austrian Academy of Sciences reports online in the journal Science about a newly discovered mechanism by which RAS proteins, central to cancer ...

Researchers stop spread of cancer in mice by blocking specific molecules

November 21, 2018
Melanoma skin cancer tumors grow larger and are more likely to metastasize due to interactions between a pair of molecules, according to experiments in mice and human cells. The results may restore the potential for a type ...

'Druggable' cancer target found in pathway regulating organ size

November 20, 2018
It's known that cancer involves unchecked cell growth and that a biological pathway that regulates organ size, known at the Hippo pathway, is also involved in cancer. It's further known that a major player in this pathway, ...

A study suggests that epigenetic treatments could trigger the development of aggressive tumours

November 20, 2018
A study headed by the Institute for Research in Biomedicine (IRB Barcelona) and published in the journal Nature Cell Biology examined whether the opening of chromatin (a complex formed by DNA bound to proteins) is the factor ...

Redefining colorectal cancer subtypes

November 20, 2018
There is a long-standing belief that colorectal cancer (CRC), which causes some 50,000 deaths in the United States each year, can be categorized into distinct molecular subtypes. In a paper published recently in the journal Genome ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.